Viral Septicemia Models for Preclinical Research
In vivo infection Viral
Viral septicemia, also referred to as systemic viral infection or viremia, occurs when viruses spread through the bloodstream, leading to multi-organ involvement and severe disease. Such infections can trigger overwhelming immune activation, cytokine storms, and high mortality, as seen in emerging pathogens like SARS-CoV-2 or severe influenza strains. Despite the clinical importance, treatment options remain limited, and there is an urgent need for effective antivirals, immunotherapies, and vaccines.
At Vibiosphen, we provide robust and translational viral septicemia models in rodents to support the development of novel antiviral compounds, immunomodulators, and vaccine candidates. Our models are designed to generate clinically relevant data that help pharmaceutical and biotechnology companies accelerate their antiviral research and development.
Background of Viral Septicemia
Systemic viral infections may originate from respiratory or gastrointestinal entry sites before spreading into the bloodstream. They can also be directly modeled by systemic inoculation routes. Their global burden is amplified by:
• The emergence of highly pathogenic viruses capable of inducing cytokine storms
• Limited therapeutic options for systemic viral diseases compared to bacterial sepsis
• The role of immune dysregulation in mortality outcomes
• The urgent need for antiviral therapies beyond supportive care
Preclinical viral septicemia models are therefore essential to assess the efficacy, safety, and mechanism of action of new therapeutic candidates.
Rodent Models of Septicemia Models
Mouse lineages
• The primary mouse lineages used in preclinical studies are inbred strains known for their genetic uniformity, which minimizes experimental variability.
Transgenic hACE2 mice (K18-hACE2 and other lines):Express the human ACE2 receptor, enabling efficient SARS-CoV-2 replication in the respiratory tract. These models are particularly valuable for studying viral pathogenesis and testing antivirals or vaccines.
GenOway hACE2 mice (for SARS-CoV-2):These mice express the human ACE2 receptor, which is essential for SARS-CoV-2 entry into host cells. They allow efficient viral replication in the respiratory tract and mimic human disease progression.
GenOway hSA/hMHC mice (for influenza and emerging respiratory viruses):Influenza research often requires models that better reflect human immune recognition. GenOway mice expressing human sialic acid receptors (hSA) and/or humanized MHC alleles provide improved susceptibility to influenza virus strains and support translational vaccine research
C57BL/6 mice have a T-helper type 1 (Th1) biased immune response, which is a cellular immune response important for fighting intracellular pathogens and cancer.
BALB/c mice have a T-helper type 2 (Th2) biased immune response. A Th2 response is a humoral immune response that relies on antibodies and is essential for combatting extracellular parasites.
• Outbred mice, unlike their inbred counterparts, are maintained in large, randomly bred colonies to maximize genetic variation. This heterogeneity makes each mouse genetically unique.
Swiss mice, OF1 and CD1
The decision to use an inbred or outbred strain depends on the specific research question. Inbred mice are for when you want to minimize all genetic variables and pinpoint the effect of a single factor. Outbred mice are for when you want to see how a factor affects a genetically varied population.
Rat lineages
• Inbred strain, meaning they are genetically uniform, and provide a consistent baseline for preclinical studies, which is essential for reproducibility.
Fischer 344 (F344) rats
• Outbred rats. They have a wide range of genetic variability, which better represents the genetic diversity found in the human population
Sprague Dawley rats
Wistar rats
The decision to use an inbred or outbred strain depends on the specific research question. Inbred rats are for when you want to minimize all genetic variables and pinpoint the effect of a single factor. Outbred rats are for when you want to see how a factor affects a genetically varied population.
Routes of Administration
Compounds under evaluation can be administered through several routes to reflect clinical usage and pharmacological profiles:
• Oral gavage
• Intraperitoneal route
• Intravenous route
• Subcutaneous route
• Intramuscular route
• Intranasal route
• Inhalation / aerosolization route
• Intratracheal route
This versatility allows us to design tailored studies that align both the infection route and the therapeutic administration route with the intended clinical application.
Viral Pathogens Studied in Vibiosphen Septicemia Models
Vibiosphen has access to validated viral strains and can also adapt models to client-specific isolates.
Respiratory Viruses Leading to Systemic Infection
• Influenza A and B (highly pathogenic strains)
• Respiratory Syncytial Virus (RSV)
• SARS-CoV-2
Other Relevant Viruses
• West Nile Virus
• And further strains available (please ask for specific pathogens including BSL3)
These models are particularly useful for evaluating antivirals, vaccines, and immunomodulators in the context of systemic viral infection.
Readouts in Viral Septicemia Models
To ensure robust and translational outcomes, Vibiosphen employs a wide range of validated endpoints:
• Viral load quantification: PCR, plaque assays, or viral titers in blood and organs (liver, spleen, kidney, lung)
• Survival and clinical scoring: Comprehensive monitoring of mouse welfare and clinical signs. Evaluation of weight loss and behavior as indicators of disease severity
• Cytokine storm analysis: Profiling of inflammatory mediators (IL-6, TNF-α, IFN-γ, IL-10)
• Histopathology and immunohistochemistry: Organ damage and viral localization
• Biomarker profiling: Markers of immune dysregulation and organ dysfunction
• Serology and neutralization assays: Evaluation of antibody responses in vaccine studies
• Imaging: Bioluminescence or fluorescence for real-time monitoring of viral spread (when available)
Applications of Vibiosphen’s Viral Septicemia Models
Our viral infection models are applied in a broad range of preclinical research applications:
• Efficacy testing of novel antivirals and immunomodulators
• Vaccine development and immunogenicity studies
• Pharmacodynamics (PD) studies to establish optimal dosing
• Host–virus interaction and immune response analysis
• Comparative efficacy against standard-of-care treatments
Why Choose Vibiosphen?
• Proven expertise in viral pathogenesis and immunology
• Access to advanced humanized mouse lines (including GenOway hACE2 and influenza models)
• Flexible and customized study designs tailored to sponsor needs
• BSL2 and BSL3 facilities for systemic viral infection research
• Strong collaborations with pharmaceutical, biotech, and academic partners
Vibiosphen combines scientific rigor with translational expertise to deliver actionable preclinical data that accelerate the development of new antivirals and vaccines for systemic viral infections.
Contact Us
If you are developing new antivirals, immunotherapies, or vaccines targeting systemic viral infections, Vibiosphen can help accelerate your research.
Contact us today to discuss your project and explore how our viral septicemia models can support your development strategy.
We will be pleased to provide a customized study design tailored to your objectives.